Launch of Mucodis® Vaginal Cream

Quantum Pharma Plc

('Quantum' or the 'Group')

Launch of Mucodis® Vaginal Cream

Quantum Pharma Plc (AIM:QP.), the growing, service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, is pleased to announce that Colonis, part of the Group's Niche Pharmaceutical division, has launched Mucodis® Vaginal Cream. The cream is part of the Mucodis® range of in-licensed patented medical devices, which focus on treating some of the side effects experienced by patients undergoing the treatment of cancer.

Mucodis® Vaginal Cream aids the treatment of painful symptoms induced by radiation vaginitis or vulvovaginitis due to radiotherapy and/or chemotherapy treatment of pelvic tumours. Of the approximately 172,000 women who are diagnosed with cancer each year, 20% (circa 34,500) will have cancers of the lower abdomen or pelvis1. This condition is known to affect patients for years after the completion of their cancer treatment2.

Approximately 352,000 patients in the UK are diagnosed annually with cancer and many experience painful or unpleasant side effects as they progress with their treatment. The Mucodis® range provides the NHS with prescribable products to address a number of the side effects associated with cancer treatments including mucositis, radiation-induced dermatitis, vulvovaginitis and proctitis. Colonis has been granted an exclusive distribution licence for these products for five years, with an option to extend beyond this initial period.

Since November 2015, Quantum has successfully launched the Mucodis® Mouthwash and Oral Mucosal Spray, Mucodis® Dermal Spray and Mucodis® Rectal Gel.  The launch of Mucodis® Vaginal Cream today is the fifth product to be launched and it completes the initial Mucodis® range.

Chris Rigg, Acting Chief Executive Officer and Chief Financial Officer of Quantum Pharma Plc, commented: "We are pleased to launch the Mucodis® Vaginal Cream to help treat the unpleasant and painful side effects of cancer treatment. This completes the initial range of our Mucodis® branded range of unique, cost effective and patented range of medical devices for the treatment of some of the side effects of oncology treatment. The cost to the NHS is highly competitive versus other products in this area.

"Whilst it is relatively early following the launch of the range, and as such we are still in the market access phase, the initial response from clinical teams at hospitals has been encouraging, and the use in their units has provided favourable patient feedback. We are positive on the outlook for the range over the short to medium term."

Footnotes:

1 http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/common-cancers-compared#heading-Two

2 http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence

- Ends -

For further information:

Notes to Editors

Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler, hospital, homecare and care home markets. Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.

Specials comprises four business units (Quantum Pharmaceutical, UL Medicines, NuPharm and Quantum Aseptics Services), which manufacture, procure and supply unlicensed medicines (specials) and special obtains. In response to a request from a prescriber for a bespoke medicine or special product to optimise patient treatment, the division manufactures, procures and supplies bespoke specials; batch made specials; aseptically prepared sterile intravenous medicines; imported medicines and special obtain products. With an expansive portfolio of products, Quantum is a trusted partner to the majority of large retail pharmacy chains in the UK, as well as pharmaceutical wholesalers, hospitals, independent pharmacies and dispensing doctors.  The division offers an unrivalled and constantly expanding range of products. It has a customer-focused, service-driven business model, which provides shorter lead times than any of its competitors.

Niche Pharmaceuticals comprises three business units (Colonis, Lamda and PERN Consumer Products) which develop and commercialise niche pharmaceuticals. This division is a product development and commercialisation business focusing on taking niche drugs through the regulatory pathway to achieve regulated status (licensed product or medical device). The division uses the excellent visibility of trends in the UK pharmacy and hospital markets gained through our Specials and Medication Adherence divisions, to allow early identification of the market opportunity to take products from unlicensed (special) status to licensed status. The division has a growing portfolio and pipeline of products that fit this unlicensed to licensed pathway, as well as complementary generic, generic plus or medical devices intended to meet unmet patient needs across a number of therapeutic areas.

Medication Adherence comprises two business units (Biodose® and Biodose Services®) which provide products and services to enhance the likelihood of a patient adhering to a medication regime, patient-focused homecare services and services to pharmaceutical companies. It owns Biodose®, the only medication delivery system on the market that accommodates both liquid and solid doses. Biodose Connect™ takes patient safety and adherence to the next level by enabling remote monitoring of adherence to medication regimes. The division also operates a range of specialist patient-focused homecare services to the NHS, private clinics and pharmaceutical companies across the UK and provides the Group with exposure to the homecare and supported living sectors of the care pathway complementing the focus of the remainder of the Group.

For further information, please visit www.quantumpharmaplc.com.